Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox Regulatory Dossier accepted for review in Canada

Jun 15, 2017Mark EdwardsNews

15 June 2017

ASX ANNOUNCEMENT

Penthrox Regulatory Dossier accepted for review in Canada

Medical Developments International Limited (ASX: MVP) is delighted to announce that the regulatory dossier for Penthrox® submitted in Canada has now been accepted for review by the Canadian regulatory body, Health Canada.

Accepting the MVP dossier for review, triggers a milestone payment of CAD$0.25 million from MVP’s partner, Purdue Pharma (Canada).

MVP Chief Executive Officer, Mr. John Sharman said: “This is another positive step towards globalizing Penthrox.”

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter